CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / Abbvie INC. (ABBV) / lutikizumab
Forward catalyst · ABBV

lutikizumab

Sponsor Abbvie INC. · listed as ABBV

READOUT Phase 3 Confidence: medium Source: clinicaltrials

lutikizumab is a drug asset sponsored by Abbvie INC., listed as ABBV. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Dec 2026 (month precision, medium confidence), tied to trial NCT06468228. That trial is in Phase 3 and currently active not recruiting, studying Hidradenitis Suppurativa.

Next catalyst

Event typeREADOUT
Expected date2026-12-31
As disclosedDec 2026
Date precisionmonth
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT06468228
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorAbbVie
Listed asABBV
Condition(s)Hidradenitis Suppurativa
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.

Get the full dataset — $499 →   More ABBV catalysts

Related catalysts and sponsor